Intravitreal anti-VEGF therapy demonstrates expanded efficacy across diverse retinal neovascular and edematous conditions beyond ARMD.
Background
Vascular endothelial growth factor (VEGF) is a key driver in the pathology of retinal and choroidal neovascularization and macular edema (ME), central to conditions like diabetic retinopathy, retinal vein occlusion (RVO), and age-related macular degeneration (ARMD). While anti-VEGF agents have revolutionized ARMD management, their potential in other retinal diseases with similar underlying mechanisms remains an active area of exploration. This review addresses the gap by consolidating evidence for anti-VEGF utility in these less common, yet vision-threatening, conditions.
Study Design
This comprehensive review synthesized current evidence on the role of anti-VEGF agents in a broad spectrum of retinal disorders. The authors focused on conditions beyond ARMD, specifically those characterized by secondary neovascularization or macular edema. The review encompassed both vascular and non-vascular disorders, drawing from published literature to summarize the therapeutic applications and efficacy of intravitreal anti-VEGF therapy in these expanded indications.
Results
The review highlights the growing application of anti-VEGF agents in numerous retinal pathologies beyond their established role in ARMD. Significant evidence supports their utility in conditions such as central serous chorioretinopathy (CSCR), macular telangiectasia type 2 (MacTel), and retinopathy of prematurity (ROP). The agents are also being explored for choroidal osteoma, tubercular granuloma, inherited retinal dystrophies, Coats' disease, angioid streaks, and retinal vasoproliferative tumors (RVPTs). Across these diverse conditions, anti-VEGF therapy targets the underlying VEGF pathway, which contributes to pathological angiogenesis and vascular leakage. This expansion signifies a broader understanding of VEGF's involvement in various ocular diseases. > The review confirms that intravitreal anti-VEGF therapy is increasingly recognized for its therapeutic potential in a wide array of retinal disorders beyond its primary indications, addressing secondary neovascularization and macular edema.
Why It Matters
This review significantly expands the perceived utility of anti-VEGF therapy, suggesting that clinicians should consider anti-VEGF agents for a broader range of retinal diseases beyond the traditional indications of ARMD, RVO, and diabetic retinopathy. For patients with less common conditions like CSCR or ROP, this offers new therapeutic avenues where options might have been limited. While specific protocols are not detailed here, the overarching message is that the VEGF pathway is a more ubiquitous target in retinal pathology than previously appreciated. This could lead to updated treatment guidelines and more widespread off-label use, pending further clinical trials for each specific condition.